PTC Therapeutics, Inc.

PTC Therapeutics, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, PTC Therapeutics, Inc. has 83.33M shares outstanding.

As of June 30, 2026, PTC Therapeutics, Inc. maintains a current ratio of 3.39, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -421.18, indicating conservative leverage, while an interest coverage ratio of 0.98 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -1.30, reflecting losses generated across the asset base. The company generates approximately 902,824.52 in revenue per employee across its workforce of 978.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.13 indicates how many times PTC Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, PTC Therapeutics, Inc. recorded an income tax benefit of -25.11M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -58.71M and -33.60M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, PTC Therapeutics, Inc. generated 882.96M in revenue and converted that into -33.60M in net income, yielding earnings per share of -0.39. EBITDA reached 158.34M, while operating income came in at 102.17M.

As of June 30, 2026, PTC Therapeutics, Inc. holds 1.95B in cash and equivalents against 609.62M in total debt, resulting in a net debt position of -401.69M. Total book value stands at -144.74M, with working capital of 1.62B providing operational flexibility.

PTC Therapeutics, Inc. produced -26.70M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -264.39M in capital expenditures, free cash flow totaled -291.09M - equivalent to -3.59 per share.

Over the twelve months ended June 30, 2026, PTC Therapeutics, Inc. posted a gross margin of 92.99, reflecting its pricing power and cost economics. The operating margin of 11.57 and net profit margin of -3.80 provide insight into operational efficiency.